Magali Le Garff-Tavernier

9PUBLICATIONS
55CO-AUTHORS
Predictive and prognostic markersHaematologyCancer therapy (excl. chemotherapy and radiation therapy)Structural properties of condensed matter
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 23, 2026
Plasma proteomics for prognostic stratification in newly diagnosed primary central nervous system lymphoma.

|Jul 04, 2026
High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

|Mar 27, 2025
Neurotoxicity in Patients With CNS Lymphomas Treated With CAR T-Cell Therapy: A Study From the French Oculo-Cerebral Lymphoma Network.

Hugo Hernández-Tost, Nicolas Weiss, Sylvain Choquet

|Aug 08, 2024
Epilepsy in Patients With Primary CNS Lymphoma: Prevalence, Risk Factors, and Prognostic Significance.

Oumaima Aboubakr, Caroline Houillier, Agusti Alentorn

|Apr 07, 2023
A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial.

Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier

|Feb 20, 2021
CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma.

Aurelian Ungureanu, Magali Le Garff-Tavernier, Myrto Costopoulos

Pageof 2

Frequent Collaborators

4 joint publications

Caroline Houillier

3 joint publications

Sylvain Choquet

3 joint publications

Agusti Alentorn

2 joint publications

Khê Hoang-Xuan